Cardax is Drug Discovery in United States that focus on macular degeneration business. Founded in 2006. They cover business area such as Cardax Inc, marketing, distribution, consumer health product, application, arthritis, metabolic syndrome, liver disease, cardiovascular disease, macular degeneration, prostate disease, astaxanthin technology, ZanthoSyn, Astaxanthin, joint health, cardiovascular health, metabolic health, liver health, maximum revenue.
2006
( 18 years old in 2024 )
Macular Degeneration
-
2800 Woodlawn Drive
Suite 129
Honolulu, HI 96822
United States
Private
Cardax Incmarketingdistributionconsumer health productapplicationarthritismetabolic syndromeliver diseasecardiovascular diseasemacular degenerationprostate diseaseastaxanthin technologyZanthoSynAstaxanthinjoint healthcardiovascular healthmetabolic healthliver healthmaximum revenue
* We use standard office opening hours in near Cardax's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Cardax is Drug Discovery business from United States that founded in 2006 (18 years old in 2024), Cardax business is focusing on Macular Degeneration.
Cardax headquarter office and corporate office address is located in 2800 Woodlawn Drive Suite 129 Honolulu, HI 96822 United States.
Cardax was founded in United States.
In 2024, Cardax is currently focus on macular degeneration sector.
Above is snippet of Google Trends for "macular degeneration" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Cardax, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
